Primary antiphospholipid syndrome

Summary

Primary antiphospholipid syndrome (MONDO:0005204) is a disease and 5 clinical trials. Top therapeutic interventions include hydroxychloroquine. A subtype of antiphospholipid syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary antiphospholipid syndrome
Mondo ID	MONDO:0005204
ICD-11	85700944
SNOMED CT	239892009
UMLS	C0409980
MedGen	592740
GARD	0024163
Is cancer (heuristic)	no

Disease family

This is a subtype of antiphospholipid syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › antiphospholipid syndrome › primary antiphospholipid syndrome

Related subtypes (3): catastrophic antiphospholipid syndrome, secondary antiphospholipid syndrome, familial antiphospholipid syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03540810	PHASE3	UNKNOWN	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome
NCT06504420	PHASE2	NOT_YET_RECRUITING	The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study
NCT05904301	Not specified	RECRUITING	Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
NCT01956188	Not specified	UNKNOWN	Omega 3 in LES and APS
NCT03459508	Not specified	COMPLETED	Ocular Findings in Women With Primary Antiphospholipid Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HYDROXYCHLOROQUINE	4	1